Butterfly Network vs HeartFlow

Heartflow trades on Nasdaq as HTFL. Its 10-K puts 2025 revenue at $176.0M, of which FFRct was 98%, and describes revenue as pay-per-use. Plaque Analysis had 489 US accounts at the end of 2025, and processing runs in the vendor's cloud from a coronary CT angiogram. Its first FFRct clearance was a De Novo, DEN130045, in November 2014, and later versions and Plaque Analysis went through 510(k). Heartflow's homepage shows no price.

Butterfly's iQ3 trade-in credit runs up to $1,500 (currency not stated) with no end date. The vendor's Affirm example is $3,119 over 36 months at about $87 a month and 0% APR, credit-dependent, currency not stated. A service reading coronary CTAs for flow assessment and plaque quantification needs Heartflow, while a small cardiology practice buying its first handheld needs the probe.